All In Biotech

NDA 022156 · Chiesi

Cleviprex

Clevidipine · Intravenous · Dihydropyridine Calcium Channel Blocker

Novel

Last checked: Nov 20, 2026Latest source record: Apr 16, 2021 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2008

Aug 1, 2008

Approved uses

1

Original approval plus efficacy supplements

Registered trials

30

15 Phase 3, 1 recruiting

FAERS reports

367

226 serious, 23 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Nov 6, 2025.

Cleviprex is indicated for the reduction of blood pressure when oral therapy is not feasible or not desirable. Cleviprex is a dihydropyridine calcium channel blocker indicated for the reduction of blood pressure when oral therapy is not feasible or not desirable. (1)

Mechanism: Clevidipine is a dihydropyridine L-type calcium channel blocker. L-type calcium channels mediate the influx of calcium during depolarization in arterial smooth muscle. Experiments in anesthetized rats and dogs show that clevidipine reduces mean arterial blood pressure by decreasing systemic vascular resistance. Clevidipine does not reduce cardiac filling pressure (pre-load), confirming lack of effects on the venous capacitance vessels.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

3 products under this application
  • CLEVIPREX · CLEVIDIPINE 50MG/100ML (0.5MG/ML) · EMULSION, INTRAVENOUS · Prescription
  • CLEVIPREX · CLEVIDIPINE 125MG/250ML (0.5MG/ML) · EMULSION, INTRAVENOUS · Discontinued
  • CLEVIPREX · CLEVIDIPINE 25MG/50ML (0.5MG/ML) · EMULSION, INTRAVENOUS · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Clevidipine" as an intervention, any sponsor and status, largest first.

All 30 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective36
  • hypotension30
  • hypoxia27
  • ventilation perfusion mismatch25
  • oxygen saturation decreased18
  • tachycardia17
  • atrial fibrillation15
  • bradycardia13
  • extravasation13
  • blood pressure inadequately controlled11
  • off label use11
  • infusion site extravasation10

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20071
200977
201018
201112
20125
20133
201417
201512
201625
20177
201821
201925
202029
202116
202224
202327
202420
202517
202611

Recalls

1 FDA enforcement reports for this application.

  • Jul 6, 2026 · Class II · Ongoing

    Lack of Assurance of Sterility

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 32 on PubMed

Sponsor: Chiesi

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.